Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment

Pharmacogenomics Journal

Volumn 13, Issue 5, 2013, Pages 430-436

  Karnes, J H ^a   McDonough, C W ^a   Gong, Y ^a   Vo, T T ^a   Langaee, T Y ^a   Chapman, A B ^b   Gums, J G ^a,c   Beitelshees, A L ^d   Bailey, K R ^e   Del Aguila, J L ^f   Boerwinkle, E A ^f   Pepine, C J ^c   Turner, S T ^b   Johnson, J A ^a,c   Cooper Dehoff, R M ^a,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Mayo Clinic   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

diabetes mellitus; hydrochlorothiazide; hypertension; KCNJ1; pharmacogenetics; ROMK1

Indexed keywords

ATENOLOL; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; POTASSIUM; TRANDOLAPRIL; VERAPAMIL;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG DOSE TITRATION; DYSGLYCEMIA; ESSENTIAL HYPERTENSION; ETHNIC DIFFERENCE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; KCNJ1 GENE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHARMACOGENOMICS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; DIABETES MELLITUS; FASTING; FEMALE; GLUCOSE; HAPLOTYPES; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROSPECTIVE STUDIES; VERAPAMIL;

EID: 84884592019     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.34     Document Type: Article

References (30)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al. Executive summary: Heart Disease and Stroke Statistics-2012 Update: a report from the American Heart Association. Circulation 2012; 125: 188-197.
2. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
3. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130-1134.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr. JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
5. Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK et al. Thiazideinduced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension 2008; 52: 30-36.
6. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-207.
7. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000; 49: 2201-2207.
8. Bozkurt O, de Boer A, Grobbee DE, de Leeuw PW, Kroon AA, Schiffers P et al. Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 2009; 22: 545-551.
9. Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens 2005; 18: 1077-1083.
10. Irvin MR, Lynch AI, Kabagambe EK, Tiwari HK, Barzilay JI, Eckfeldt JH et al. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens 2010; 28: 2076-2083.
11. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48: 219-224.
12. Shafi T, Appel LJ, Miller III ER , Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52: 1022-1029.
13. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009; 157: 442-449.
14. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998; 32: 1228-1237.
15. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
16. Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890-894.
17. Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF et al. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther 2009; 7: 1329-1340.
18. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 2008; 3: e3583.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
20. Cooper-DeHoff RM, Aranda Jr. JM , Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients-findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J 2006; 151: 1072-1079.
21. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960; 21: 21-27.
22. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
23. Welling PA, Ho K. A comprehensive guide to the ROMK potassium channel: form and function in health and disease. Am J Physiol Renal Physiol 2009; 297: F849-F863.
24. Braun M, Ramracheya R, Bengtsson M, Zhang Q, Karanauskaite J, Partridge C et al. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes 2008; 57: 1618-1628.
25. Chatterjee R, Yeh HC, Shafi T, Selvin E, Anderson C, Pankow JS et al. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: The Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2010; 170: 1745-1751.
26. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM et al. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy 2009; 29: 1157-1165.
27. Goldman N, Lin IF, Weinstein M, Lin YH. Evaluating the quality of self-reports of hypertension and diabetes. J Clin Epidemiol 2003; 56: 148-154.
28. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110: 1572-1578.
29. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339-1346.
30. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.